TCGA-A7-A13D-01A-13R-A12P-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 32
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HYPOXIA+0.490
- MYC_TARGETS_V2+0.480
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.460
- GLYCOLYSIS+0.400
- G2M_CHECKPOINT+0.380
- APICAL_JUNCTION+0.340
- E2F_TARGETS+0.330
- NOTCH_SIGNALING+0.330
- CHOLESTEROL_HOMEOSTASIS+0.320
- MITOTIC_SPINDLE+0.320
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.280
- BILE_ACID_METABOLISM-0.270
- FATTY_ACID_METABOLISM-0.250
- INTERFERON_ALPHA_RESPONSE-0.220
- INTERFERON_GAMMA_RESPONSE-0.210
- DNA_REPAIR-0.200
- ESTROGEN_RESPONSE_EARLY-0.150
- HEME_METABOLISM-0.130
- IL6_JAK_STAT3_SIGNALING-0.130
- PROTEIN_SECRETION-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MBCProject_2290_T2_RNA | — | E | 0.838 |
| 2 | TCGA-34-5236-01A-21R-1820-07 | — | cohortSQ1 | 0.821 |
| 3 | MBCProject_6310_T1_RNA | — | C | 0.814 |
| 4 | TCGA-E2-A1LL-01A-11R-A144-07 | — | C | 0.813 |
| 5 | TCGA-D8-A27F-01A-11R-A16F-07 | — | E | 0.812 |
| 6 | MNG1297 | — | — | 0.812 |
| 7 | SRR2771207 | — | — | 0.802 |
| 8 | TCGA-46-6025-01A-11R-1820-07 | — | cohortSQ2 | 0.785 |
| 9 | MNG1272 | — | — | 0.779 |
| 10 | C3L-02168 | — | cohortSQ2 | 0.773 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HYPOXIA | 0.490 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.480 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.460 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.400 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.380 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.340 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.330 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.330 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.320 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.320 | Inavolisib | — uncovered |
| MYOGENESIS | 0.320 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.290 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.270 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.250 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.240 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.230 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| COAGULATION | 0.180 | Binimetinib | — uncovered |
| MYC_TARGETS_V1 | 0.160 | Inavolisib | — uncovered |